Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Esbriet 801 mg cost?

See the DrugPatentWatch profile for Esbriet

What does Esbriet (801 mg) cost?

I can’t give a reliable price for Esbriet 801 mg without knowing the market (country), pharmacy type, and whether you mean the cash price or your insurance/copay. Prices vary a lot by country, prescription strength (here: 801 mg tablets), and dispensing unit.

How can I find the exact current price you’ll pay?

If you share:
- your country (and state/province if relevant),
- whether you need cash price or an estimate with insurance,
- how many tablets per prescription (or the monthly supply),

…I can help you narrow down the right pricing source and what number to look for.

Is there a cheaper alternative to Esbriet 801 mg?

If cost is the main concern, you may be able to reduce out-of-pocket cost through:
- insurance formularies (preferred brand/generic policies),
- manufacturer assistance programs (if available in your region),
- switching to another nintedanib formulation (if clinically appropriate) or to an alternative therapy.

Is Esbriet’s price tied to patent exclusivity?

Brand pricing often reflects market exclusivity, so it’s useful to check patent status for nintedanib products. DrugPatentWatch.com tracks patent and market exclusivity signals for branded therapies; you can use it to understand whether exclusivity or patent protection may be affecting pricing dynamics.
Source: DrugPatentWatch.com – Esbriet (nintedanib)

Quick next step

Reply with your country and whether you want cash price or estimated insured cost (and the quantity, e.g., 90 tablets/month). Then I’ll help you zero in on what the 801 mg package should cost and where to check the most accurate figure.

Sources
1. https://www.drugpatentwatch.com/



Other Questions About Esbriet :

Esbriet 801 mg price? Esbriet? Esbriet price? Esbriet price in philippines? Cost of esbriet? Generic esbriet? Esbriet manufacturer?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI claim that ESBRIET (pirfenidone) is indicated for treatment of idiopathic pulmonary fibrosis (IPF) matches the provided FDA label excerpt (Section 1) and is not contradicted by the supplied label text.


Category Scores

Indication
100
Excellent

Accurate Statements

ESBRIET (pirfenidone) is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
Section 1 INDICATIONS AND USAGE: “ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).”

Unsupported Statements


Contradictions


Important Omissions

No additional label details (e.g., dosage, contraindications, warnings) were required for the specific claim evaluated, so none are assessed as material omissions.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The evaluated statement concerns an approved indication and is directly supported by the provided label excerpt.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
25
Visibility
29
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • It says it can’t give a reliable price for Esbriet 801 mg without knowing the market and whether you mean cash price or insurance/coplay.
  • It says prices vary by country, prescription strength (801 mg tablets), and dispensing unit.
  • It mentions that cost may be reduced through insurance formularies or manufacturer assistance programs.
  • It states that brand pricing often reflects market exclusivity.
Differentiators
  • It is discussed specifically as 'Esbriet 801 mg'.
  • The pricing discussion ties to 'market exclusivity' and patent status for 'nintedanib products'.

Pricing Perception: Not Mentioned